1-5 of 5
Peter Ganly, BMBCh, PhD
Close
Sort by
Journal Articles

Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

Alessandra Di Bacco, PhD, Nizar J. Bahlis, MD, Nikhil C Munshi, MD, Hervé Avet-Loiseau, MD PhD, Tamás Masszi, MD, Luísa Viterbo, MD, Ludek Pour, MD PhD, Peter Ganly, BMBCh, PhD, Michele Cavo, MD, Christian Langer, MD, Shaji Kumar, MD, S. Vincent Rajkumar, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Bin Li, Sunita Badola, Lei Shen, Jacob Zhang, Ling Wang, PhD, Dixie-Lee Esseltine, MD, Katarina Luptakova, Helgi van de Velde, MD PhD, Paul G. Richardson, MD, Philippe Moreau
Journal: Blood
Blood (2016) 128 (22): 243.
https://doi.org/10.1182/blood.V128.22.243.243
Published: 2016
Journal Articles

Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data

Moritz Gerstung, PhD, Elli Papaemmanuil, PhD, Inigo Martincorena, PhD, Lars Bullinger, MD, Verena I. Gaidzik, MD, Peter Paschka, MD, Michael Heuser, MD, Felicitas Thol, MD, Niccolo Bolli, MD PhD, Peter Ganly, BMBCh, PhD, Arnold Ganser, MD, Ultan McDermott, MD PhD, Michael R Stratton, MD PhD, Konstanze Döhner, MD, Hartmut Döhner, Prof. Dr., Richard F. Schlenk, MD, Peter J Campbell, MD PhD
Journal: Blood
Blood (2015) 126 (23): 85.
https://doi.org/10.1182/blood.V126.23.85.85
Published: 2015
Journal Articles

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Philippe Moreau, Tamás Masszi, MD, Norbert Grzasko, MD PhD, Nizar J Bahlis, MD, Markus Hansson, Ludek Pour, MD, Irwindeep Sandhu, MD, Peter Ganly, BMBCh, PhD, Bartrum W Baker, MBChB, FRACP, FRCPA, Sharon Jackson, MBChB, FRACP, FRCPA, Anne-Marie Stoppa, MD, David R Simpson, MBChB, FRACP, FRCPA, Peter Gimsing, MD DMSci, Antonio Palumbo, Laurent Garderet, MD, Michele Cavo, Shaji K. Kumar, MD, Cyrille Touzeau, MD, Francis Buadi, MD, Jacob P. Laubach, MD, Jianchang Lin, PhD, Deborah Berg, RN, MSN, Alessandra DiBacco, PhD, Ai-Min Hui, MD PhD, Paul G. Richardson, MD
Journal: Blood
Blood (2015) 126 (23): 727.
https://doi.org/10.1182/blood.V126.23.727.727
Published: 2015
Journal Articles

A Next Generation Sequencing-Based Approach to Detect Gene Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma

Niccolo Bolli, MD PhD, Graham R Bignell, PhD, Peter Ganly, BMBCh, PhD, Elli Papaemmanuil, PhD, Herve Avet-Loiseau, Adam Sperling, MD PhD, Stephane Minvielle, Peter J Campbell, PhD, Nikhil C. Munshi, MD
Journal: Blood
Blood (2014) 124 (21): 3364.
https://doi.org/10.1182/blood.V124.21.3364.3364
Published: 2014
Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD
Journal: Blood
Blood (2008) 112 (11): lba-1.
https://doi.org/10.1182/blood.V112.11.lba-1.lba-1
Published: 2008